My ePortfolio Register   

Genetic alterations that make a type of brain cancer more aggressive were identified

Among the various types of cancerous brain tumours, 70% are astrocytomas. Fatal in as many as 90% of cases, astrocytomas originate in the largest and most numerous cells in the central nervous system, called astrocytes because of their star shape.

A study conducted by biologist Valeria Valente, a researcher at São Paulo State University's School of Pharmaceutical Sciences (FCF-UNESP), in Brazil, with support from the São Paulo Research Foundation (FAPESP), set out to identify the mechanisms that make astrocytomas so aggressive and to find ways to customise treatment to patient needs.

The study identified the genetic alterations with the most potential to promote aggressiveness, pointing to possible biomarkers of prognosis and genes that could be candidate therapeutic targets.

"We discovered a very strong correlation between alterations in the expression of astrocytoma cell repair genes and patient survival prognosis," Valente said.

The study focused on glioblastomas, the most aggressive of the four subtypes into which the World Health Organisation (WHO) classifies astrocytomas: patients with this type of tumour survive 14 months on average.

"The point was to characterise the cellular alterations that promote the aggressive behaviour of glioblastomas, tumours with a very high mortality rate.

They're practically untreatable owing to their aggressiveness and their location in as delicate and vital an organ as the brain," Valente explained.

Performed under the auspices of the Center for Cell-Based Therapy (CTC), one of the Research, Innovation and Dissemination Centers (RIDCs) supported by FAPESP, the study was published in Tumor Biology.

Valente and her team worked on astrocytoma cells collected from 55 patients submitted to surgical resection for tumour removal at the general hospital of the University of São Paulo's School of Medicine of Ribeirão Preto (FMRP-USP), looking for gene expression signatures associated with patient survival time.

The samples analysed included cells from 42 glioblastomas (grade IV) and from 12 astrocytomas (six grade III and six grade II), which are still fatal but much less aggressive - patient survival can reach five years.

"In these comparisons, we found 19 genes with significantly altered expression. It was diminished in some genes, but in most cases, it was greatly augmented. Some genes were expressed as much as 100 times more highly in tumour tissue than healthy tissue," Valente said.

"We then defined gene expression signatures representing these alterations, in isolation and in all possible combinations, and investigated whether there was a correlation between the presence of the signature and patient survival."

The search was conducted using publicly available data from a much larger set of cases, giving the study statistical strength.

Once they had detected the genetic signatures in the samples, they separated the patients into two groups according to the presence or absence of a specific signature.

The researchers found the average survival time for each group and identified signatures that correlated with shorter prognoses, establishing a methodology capable of predicting the aggressiveness of the disease based on the presence of each gene signature.

"An alteration in just one gene could correlate with a worse prognosis," Valente said. "We developed a strategy to correlate gene signatures with tumour behaviour. This can be used to predict patient prognosis and drive the development of novel therapies."

Until a cure is found for the most aggressive astrocytomas, the priority for oncologists is to detect their existence as early as possible so that treatment by surgery, radiation and/or chemotherapy can begin rapidly and patient survival can be prolonged.

Source: FAPESP

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence